Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.
https://www.pharmalive.com/wp-content/uploads/2020/11/Calliditas-Eyes-Approval-for-IgaN-Treatment-Following-Positive-Late-Stage-Study-Results-BioSpace-11-9-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-11-09 13:44:492020-11-09 13:46:38Calliditas Eyes Approval for IgaN Treatment Following Positive Late-Stage Study Results